Broader coverage does not remove the need for a focused question
Whole-genome sequencing reads across most of the genome and can detect a wider range of variant types than many targeted tests. Its practical advantage depends on laboratory validation, analysis pipeline and the suspected disorder.
More data also produce more uncertain findings. A genome should be ordered with a phenotype, inheritance model and plan for confirmation—not as an unlimited search for every possible explanation.
The laboratory should state which missed variant classes or poorly covered regions are relevant to the case.
Who may be considered?
This review may help when the phenotype and existing evidence create a focused question about clinical whole-genome sequencing.
- A strong genetic phenotype after unrevealing panel or exome testing.
- A disorder where structural, intronic or other variant classes are plausible.
- A family needing one integrated analysis instead of sequential tests.
- A prior genome requiring reinterpretation with updated phenotype.
- A patient considering research-grade versus clinical-grade testing.
What the specialist team must confirm
The team reviews prior sequencing quality and raw files, phenotype, pedigree, suspected inheritance, sample strategy, laboratory validation, secondary-finding consent and whether a different test such as repeat expansion or methylation analysis remains necessary.
Key points for this treatment
From unresolved phenotype to genome-wide analysis
Genome breadth is paired with disciplined prioritization, confirmation and transparent reporting of limitations.
Confirmation, data stewardship and future reinterpretation
Potentially diagnostic variants are confirmed and correlated with the clinical picture. Results affecting relatives or reproduction require counselling and sometimes targeted family testing.
Because interpretation evolves, clarify data retention, privacy, recontact and reanalysis policies. Another specialized assay may still be needed after a negative genome.
Limits, burdens and realistic expectations
Genome sequencing does not read every region accurately, and repeat, methylation, mosaic or tissue-specific disorders may require other methods. Uncertain findings are common, privacy stakes are high and a result may not change treatment.
Acute metabolic, neurologic, cardiac or respiratory deterioration needs immediate local management, not delayed care while awaiting genomic interpretation.